Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525740 · ClinicalTrials.gov registry record · Phase 4
Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery
A Phase 4 study of Malignant Female Reproductive System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06525740: Recruiting Phase 4 study of Malignant Female Reproductive System Neoplasm, sponsored by Mayo Clinic.
NCT06525740 is a Phase 4 study of Malignant Female Reproductive System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 140 participants, below the 397-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525740, a Phase 4 study of Malignant Female Reproductive System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in the central nervous system and is a long-acting opioid pain medication. Intrathecal hydromorphone works by changing the way the brain and nervous system respond to pain and is similar to an epidural. This trial may help researchers determine if methadone works as well as intrathecal hydromorphone for pain relief after surgery in patients with gynecologic cancer.
Primary Outcome
Will be assessed per group \[intravenous (IV) methadone or intrathecal (IT) hydromorphone\] by patient-reported pain on a scale of 0-10 where 0=no pain and 10=worst pain imaginable.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Methadone
- DRUG Hydromorphone
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 4 |
What NCT06525740 shows while recruiting
NCT06525740 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 397-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT06525740 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06525740 about?
NCT06525740 is a clinical study titled "Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery". This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in t...
What is the current status of trial NCT06525740?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2024-09-03. Estimated completion is 2029-09-01.
What conditions does trial NCT06525740 study?
This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm.
What interventions are being tested in trial NCT06525740?
The interventions under investigation include: Questionnaire Administration (OTHER), Methadone (DRUG), Hydromorphone (DRUG).
Who is sponsoring clinical trial NCT06525740?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06525740 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Female Reproductive System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06525740's enrollment target sits among peer trials
140 10th of 18 higher than 9 of 18 other Malignant Female Reproductive System Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Female Reproductive System Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
RECRUITING · NA
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
RECRUITING · Phase 2
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
-
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
RECRUITING
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI